ImageneBio Inc
ImageneBio Inc (IMA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ima · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$1.33
Consensus
$1.33
-76.4% upside
Low
$1.33
Median: $1.33 · Last Close: $5.63
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $5.59 | ↓ 0.79% |
1-day model range: $5.49–$5.68. Peak: $5.68 (-0.79%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · IMA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-11 | Wedbush | Maintains | Underperform→Underperform |
| 2025-07-25 | Wedbush | Maintains | Neutral→Neutral |
| 2024-11-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-29 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2024-05-14 | Wedbush | Maintains | Outperform→Outperform |
| 2024-03-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-03-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-01-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on ImageneBio Inc (IMA) stock. Of the recent 28 rating actions, 0 were upgrades and 1 were downgrades. 5 analysts currently cover IMA.
Analyst Recommendation Trends
IMA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↑ 452.8% YoY
Revenue Next Year
$0M
↓ 57.5% YoY
EPS This Year
$-4.10
EPS Next Year
$-3.07
↓ 25.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast IMA EPS of $-4.10 for the current fiscal year, based on estimates from 2 analysts. The IMA revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IMA stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IMA price target is $1.33 (-76.4% upside), with an analyst consensus of Buy.
The IMA short-term stock prediction for tomorrow is $5.59 (-0.79%). The IMA stock prediction for 2030 projects a range of $2–$2.
ImageneBio Inc trades on NASDAQ under the ticker IMA. The IMA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.
Frequently asked questions
IMA forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month IMA price target is $1.33, with a high forecast of $1.33 and a low of $1.33. The median price target is shown in the chart above when available. This implies -76.4% potential upside from the current price of $5.63.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.